- Home
- ESPR vs CVRX Comparison
ESPR vs CVRX Comparison
Compare ESPR & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- CVRX
- Stock Information
- Founded
- ESPR 2008
- CVRX 2000
- Country
- ESPR United States
- CVRX United States
- Employees
- ESPR N/A
- CVRX N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ESPR Health Care
- CVRX Health Care
- Exchange
- ESPR Nasdaq
- CVRX Nasdaq
- Market Cap
- ESPR 202.2M
- CVRX 174.4M
- IPO Year
- ESPR 2013
- CVRX 2021
- Fundamental
- Price
- ESPR $1.20
- CVRX $6.86
- Analyst Decision
- ESPR Buy
- CVRX Buy
- Analyst Count
- ESPR 6
- CVRX 7
- Target Price
- ESPR $6.50
- CVRX $14.50
- AVG Volume (30 Days)
- ESPR 3.1M
- CVRX 171.6K
- Earning Date
- ESPR 08-11-2025
- CVRX 07-28-2025
- Dividend Yield
- ESPR N/A
- CVRX N/A
- EPS Growth
- ESPR N/A
- CVRX N/A
- EPS
- ESPR N/A
- CVRX N/A
- Revenue
- ESPR $259,574,000.00
- CVRX $52,870,000.00
- Revenue This Year
- ESPR $4.07
- CVRX $11.53
- Revenue Next Year
- ESPR N/A
- CVRX $18.61
- P/E Ratio
- ESPR N/A
- CVRX N/A
- Revenue Growth
- ESPR 12.99
- CVRX 25.62
- 52 Week Low
- ESPR $0.69
- CVRX $4.30
- 52 Week High
- ESPR $3.94
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- ESPR 63.86
- CVRX 61.51
- Support Level
- ESPR $1.10
- CVRX $6.30
- Resistance Level
- ESPR $1.26
- CVRX $7.21
- Average True Range (ATR)
- ESPR 0.08
- CVRX 0.35
- MACD
- ESPR 0.02
- CVRX 0.16
- Stochastic Oscillator
- ESPR 93.55
- CVRX 83.24
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.